These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32407451)

  • 1. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
    JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial.
    Gershoni A; Tiosano A; Ben Ishai M; Barayev E; J Ben Simon G; Yassur I
    Eye (Lond); 2022 Feb; 36(2):407-413. PubMed ID: 33692538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
    Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
    Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
    Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
    Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
    Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
    Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I
    Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
    Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
    J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.
    Cox KF; Margo CE
    Cancer Control; 2016 Apr; 23(2):133-9. PubMed ID: 27218790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
    Sagiv O; Nagarajan P; Ferrarotto R; Kandl TJ; Thakar SD; Glisson BS; Altan M; Esmaeli B
    Br J Ophthalmol; 2019 Jun; 103(6):775-780. PubMed ID: 30021814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
    Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
    González AR; Etchichury D; Gil ME; Del Aguila R
    Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
    Barker CA; Dufault S; Arron ST; Ho AL; Algazi AP; Dunn LA; Humphries AA; Hultman C; Lian M; Knott PD; Yom SS
    J Clin Oncol; 2024 Jul; 42(19):2327-2335. PubMed ID: 38630954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.